CD274 and neoplasm: In addition to PD-L1 expression, tumor mutation burden, defined as the number of somatic nonsynonymous mutations per mega base, could potentially predict response to immunotherapy; higher tumor mutation burden is associated with improved therapy response [15,16,24].